As a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, it may surpass even tirzepatide for weight loss based on early clinical data
Between rides and food, I was, like, their best customer
PLoS ONE 9 , e100778 (2014)
Neuropsychiatric Disorders and the Gut-Brain Axis The microbiomegut-brain axis does not only affect the gastrointestinal system, but it has a role in the development of various behavioral and neurodegenerative diseases
Wegovy is a higher-dose formulation of semaglutide specifically approved for weight management in individuals without diabetes
Pu essere utilizzato in monoterapia quando la metformina non appropriata per controindicazioni o intolleranza, oppure in associazione ad altri medicinali per il diabete, inclusi antidiabetici orali e insulina basale, secondo le necessit cliniche